You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Evidence-based due – an integrative benefit-risk decision making on proton pump inhibitors
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-HPS-054
- By: HSIEH, Hui-Hsia (Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Pharmacy, Taichung, China Taiwan)
- Co-author(s): Hui-Hsia Hsieh:
Tien-Yuan Wu: Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China;Pharmacology, Tzu Chi University, Hualien, Taiwan, Province of China
Hsun-Yang Chuang: Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China
Chi-Hua Chen: Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China
Mann-Jen Hour: Pharmacy, China Medical University, Taichung, Taiwan, Province of China - Abstract:
Background
The American College of Gastroenterology recommendations that high-dose continuous infusion of proton pump inhibitors (PPIs) should be given to the high-risk bleeding ulcer patients after endoscopic management. The other meta-analysis studies showed that non-high dose intermittent PPI therapy is not inferior to high-dose continuous.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026